Business
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed","length":109,"tagName":"p"},{"type":"text","content":"ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement.","length":646,"tagName":"p"},{"type":"text","content":"The Company has made meaningful progress on its strategic plans for 2026 and expects to share additional details in the coming weeks. The Company believes that regaining compliance with this listing requirement positions it well for 2026.","length":238,"tagName":"p"},{"type":"text","content":"About Aspire Biopharma Holdings, Inc.","length":37,"tagName":"p"},{"type":"text","content":"Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.","length":534,"tagName":"p"},{"type":"text","content":"For more information, please visit www.aspirebiolabs.com","length":56,"tagName":"p"},{"type":"text","content":"Aspire Biopharma Holdings, Inc.","length":31,"tagName":"p"},{"type":"text","content":"Contact","length":7,"tagName":"p"},{"type":"text","content":"PCG AdvisoryKevin [email protected]","length":64,"tagName":"p"},{"type":"text","content":"Safe Harbor Statement","length":21,"tagName":"p"},{"type":"text","content":"This press release contains "forward-looking statements" within the...